Identification of drug resistance mutations in HIV from constraints on natural evolution

TL;DR

This study uses an Ising model based on HIV sequence data to predict resistance mutation sites, aiding in understanding viral evolution and informing the design of more robust therapies.

Contribution

The paper introduces a novel application of an Ising model to identify HIV resistance mutations from pre-treatment sequence data, advancing viral evolution modeling.

Findings

Successfully predicted resistance mutation sites

Demonstrated the model's potential for guiding therapy design

Progressed understanding of HIV's fitness landscape

Abstract

Human immunodeficiency virus (HIV) evolves with extraordinary rapidity. However, its evolution is constrained by interactions between mutations in its fitness landscape. Here we show that an Ising model describing these interactions, inferred from sequence data obtained prior to the use of antiretroviral drugs, can be used to identify clinically significant sites of resistance mutations. Successful predictions of the resistance sites indicate progress in the development of successful models of real viral evolution at the single residue level, and suggest that our approach may be applied to help design new therapies that are less prone to failure even where resistance data is not yet available.